Phase 2 N=21 Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA
Prostate Cancer
Primary: PSA Response, as Defined by ≥ 50% Decrease in PSA From Baseline — 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Sequential Vaccinations in Prostate Cancer Patients
Prostatic Neoplasms
Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants
Phase 2 N=80 Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Prostate Cancer
Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…
Phase 4 N=62 Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Prostate Cancer
Primary: To Compare Urinary Bladder Radioactivity Observed on Piflufolastat (18F) PET and Flotufolastat (18F) PET. — 29.0; 10.9 ratio — p=<0.001
Phase 2 N=20 PSMA Imaging of Localized Prostate Cancer
Prostate Cancer
Primary: The Number of Subjects With PSMA-positive (Prostate-specific Membrane Antigen) "Dominant" PC Lesion(s) Greater Than 5mm in Diameter, Whose Lesion(s) Have Been…
Phase 3 N=163 Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants Achieving Chemical Castration (Defined as Testosterone Levels ≤ 0.5 ng/mL) at Days 28, 84, and 168. — 98.1 percentage of participants
Phase 3 N=30 Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg
Prostatic Neoplasms
Primary: Number of Participants With Adverse Events — 12; 1; 4 Participants
Phase 3 N=165 FACBC Outcomes for Post Prostatectomy
Prostate Cancer
Primary: Failure-free Survival — 75.5; 63.0 Percentage of participants
Phase 3 N=221 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment
Prostate Cancer
Primary: The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Planned Treatment Through Detection of Disease. — 126; 87; 88; 34 Participants
N/A N=18 LC Bead LUMI for Prostatic Artery Embolization
BPH
Primary: Mean Change in IPSS Score — -11.4 units on a scale
Phase 2 N=43 Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Progression Free Survival — 85.3 percentage of participants
N/A N=31 Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
Adenocarcinoma of the Prostate
Primary: Number of Putative Sites of Metastatic Disease as Determined by 18F-DCFPyL PET/CT — 21; 5; 5 Participants
Phase 1 N=41 A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Prostate Specific Antigens · Prostate Neoplasms
Primary: Number of Participants With a Positive Immune Response Following Vaccination Determined by Interferon (IFN) Gamma Enzyme-linked Immunosorbent Spot (ELISpot) — 12; 10…
N/A N=84 Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer
Prostate Cancer
Primary: Incidence of Grade 3+ Gastrointestinal Toxicity — 0 participants
Phase 3 N=310 A Study of Leuprolide to Treat Prostate Cancer
Prostate Cancer
Primary: Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: Intent-to-treat (ITT) Population for the Primary…
Phase 3 N=115 A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Negative Biopsies at Month 12 — 28; 17 Participants — p=0.0318
Phase 2 N=40 PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Prostate Neoplasms
Primary: The Purpose of the Present Study is to Assess the Safety of PS-341 as a Pretreatment in Patients Who Are to Undergo a Radical Prostatectomy. Poor Wound Healing and…
Phase 2 N=37 Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients With Undetectable PSA (Prostate-Specific Antigen) at 1 Year — 54.54 percentage of participants
Phase 2 N=25 FACBC for Recurrent Prostate Cancer
Recurrent Prostate Cancer
Primary: The Presence of Cancer Tissue Inside of the Prostate Bed — 13; 8; 1; 0 Participants
N/A N=10 A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine
Prostate Cancer
Primary: Number of Participants With Antigen-specific Interferon- Secretion as Measured by Enzyme-linked Immunospot (ELISPOT) Assay — 4 participants
Phase 2 N=24 An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate
Prostate Cancer
Primary: Proportion of Patients Showing PSA Nadir — 83 percentage of patients with PSA nadir
Phase 4 N=1,658 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years
Prostatic Hyperplasia
Primary: Number of Men With Confirmed Diagnosis of BPH — 386; 437 Participants
N/A N=35 Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study
Prostate Cancer
Primary: Feasibility - Recruitment — 39 Participants
Phase 2 N=16 Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 2; 6; 3 Participants
Phase 3 N=109 Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
Metastatic Prostate Cancer
Primary: Evidence of Metastatic Prostate Cancer — 0; 36; 0; 10 Participants
Phase 2 N=13 Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
Prostate Cancer
Primary: PET Detection of Primary Prostate Cancer — 6; 7 Participants
N/A N=146 Trial of Community Health Worker-led Decision Coaching
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Screening Rates — 77.8; 76.7 Percentage of participants
Phase 2 N=56 Hypofractionation Proton Beam Therapy With Concurrent Treatment of Prostate and Pelvic Nodes for Prostate Cancer
Prostate Cancer
Primary: Late Grade ≥ 3 Gastrointestinal (GI) and Genitourinary (GU) Toxicity of Interest, Using the CTCAE v4.0 — 1; 0 Participants
N/A N=408 Prostate Cancer Screening Trial Using Imaging
Prostate Neoplasm
Primary: The Proportion of Men With a Positive MRI Defined by a Score of 3 or Greater — 17.7 Percentage of participants
Phase 4 N=383 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
Prostate Cancer
Primary: Pre/Post Ratio PSA Area Under the Curve (AUC) — 0.57; 0.61 Ratio